SYN3 and ocular melanoma: The rate of severe AEs also seems to be better in rAd-IFNa/Syn3 compared to CPI and CPI combination therapies: only 3.8% of patients had ≥G3 AEs compared to 8.0%, 12.9%, and 16.9% for Durvalumab + OM, Pembrolizumab, and Atezolizumab, respectively.